BACKGROUND: Between May 2003 and April 2005, a population-based surveillance of Candida bloodstream infections was conducted in Quebec. A total of 453 episodes of candidemia (464 yeast isolates) from 54 participating hospitals were studied. RESULTS: The annual incidence rate was three per 100,000 population. Global hospital mortality was 38%. The most common predisposing factors were the presence of an intravascular catheter (80%), use of antibacterial therapy (67%), stay in an intensive care unit (49%), use of parenteral nutrition (32%) and intra-abdominal surgery (31%). Fluconazole alone or in association with other antifungals was used for treatment in over 80% of cases. Candida albicans comprised 62% of isolates, followed by Candida glabrata (17%), Candida parapsilosis (9%), Candida tropicalis (5%), Candida lusitaniae (3%) and Candida krusei (3%). Of the 288 C albicans isolates, seven (2%) were resistant to flucytosine, one to fluconazole and none to itraconazole or voriconazole. Of the 75 non-C albicans species isolates with reduced susceptibility to fluconazole (minimum inhibitory concentration [MIC] 16 mug/mL or greater), none were susceptible to itraconazole (MIC 0.12 mg/L or lower), whereas 71 (95%) were susceptible to voriconazole (MIC 1 mug/mL or lower). However, only five of 12 (42%) fluconazole-resistant isolates were susceptible to voriconazole. Posaconazole, ravuconazole and caspofungin displayed a broad spectrum of activity against these isolates, with MICs of 1 mg/L or lower in 56%, 92% and 100% of isolates, respectively. Overall, a correlation (r(2)>0.87) was observed among increasing fluconazole MICs and the geometric mean MICs of itraconazole, voriconazole, posaconazole and ravuconazole. CONCLUSIONS: These surveillance results when compared with those of the 1993 to 1995 survey confirm little variation in the distribution of species causing invasive Candida infection over a 10-year period in Quebec, as well as the continuous excellent overall in vitro activity of fluconazole.
BACKGROUND: Between May 2003 and April 2005, a population-based surveillance of Candida bloodstream infections was conducted in Quebec. A total of 453 episodes of candidemia (464 yeast isolates) from 54 participating hospitals were studied. RESULTS: The annual incidence rate was three per 100,000 population. Global hospital mortality was 38%. The most common predisposing factors were the presence of an intravascular catheter (80%), use of antibacterial therapy (67%), stay in an intensive care unit (49%), use of parenteral nutrition (32%) and intra-abdominal surgery (31%). Fluconazole alone or in association with other antifungals was used for treatment in over 80% of cases. Candida albicans comprised 62% of isolates, followed by Candida glabrata (17%), Candida parapsilosis (9%), Candida tropicalis (5%), Candida lusitaniae (3%) and Candida krusei (3%). Of the 288 C albicans isolates, seven (2%) were resistant to flucytosine, one to fluconazole and none to itraconazole or voriconazole. Of the 75 non-C albicans species isolates with reduced susceptibility to fluconazole (minimum inhibitory concentration [MIC] 16 mug/mL or greater), none were susceptible to itraconazole (MIC 0.12 mg/L or lower), whereas 71 (95%) were susceptible to voriconazole (MIC 1 mug/mL or lower). However, only five of 12 (42%) fluconazole-resistant isolates were susceptible to voriconazole. Posaconazole, ravuconazole and caspofungin displayed a broad spectrum of activity against these isolates, with MICs of 1 mg/L or lower in 56%, 92% and 100% of isolates, respectively. Overall, a correlation (r(2)>0.87) was observed among increasing fluconazole MICs and the geometric mean MICs of itraconazole, voriconazole, posaconazole and ravuconazole. CONCLUSIONS: These surveillance results when compared with those of the 1993 to 1995 survey confirm little variation in the distribution of species causing invasive Candida infection over a 10-year period in Quebec, as well as the continuous excellent overall in vitro activity of fluconazole.
Authors: Manuel Cuenca-Estrella; Dolores Rodriguez; Benito Almirante; Juliette Morgan; Ana Maria Planes; Manel Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Margarita Salvado; David W Warnock; Albert Pahissa; Juan L Rodriguez-Tudela Journal: J Antimicrob Chemother Date: 2004-12-23 Impact factor: 5.790
Authors: J H Rex; P W Nelson; V L Paetznick; M Lozano-Chiu; A Espinel-Ingroff; E J Anaissie Journal: Antimicrob Agents Chemother Date: 1998-01 Impact factor: 5.191
Authors: A S Kao; M E Brandt; W R Pruitt; L A Conn; B A Perkins; D S Stephens; W S Baughman; A L Reingold; G A Rothrock; M A Pfaller; R W Pinner; R A Hajjeh Journal: Clin Infect Dis Date: 1999-11 Impact factor: 9.079
Authors: M A Pfaller; D J Diekema; D L Gibbs; V A Newell; J F Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega Journal: J Clin Microbiol Date: 2007-04-18 Impact factor: 5.948
Authors: Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh Journal: Can J Infect Dis Med Microbiol Date: 2010 Impact factor: 2.471
Authors: Ana Alastruey-Izquierdo; Alicia Gómez-López; Maiken C Arendrup; Cornelia Lass-Florl; William W Hope; David S Perlin; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella Journal: J Clin Microbiol Date: 2012-04-25 Impact factor: 5.948
Authors: Shawn R Lockhart; Naureen Iqbal; Angela A Cleveland; Monica M Farley; Lee H Harrison; Carol B Bolden; Wendy Baughman; Betsy Stein; Rosemary Hollick; Benjamin J Park; Tom Chiller Journal: J Clin Microbiol Date: 2012-08-08 Impact factor: 5.948
Authors: M Puig-Asensio; M Fernández-Ruiz; J M Aguado; P Merino; D Lora-Pablos; J Guinea; P Martín-Dávila; M Cuenca-Estrella; B Almirante Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191